|
Site Search
|
Takara Bio Reports on Cancer Drug Trial in China
publication date: May 5, 2008
Takara Bio Inc. of Japan has begun a collaboration with Tianjin Cancer Institute & Hospital, Tianjin Medical University, under which Tianjin Cancer Institute & Hospital has initiated clinical research of a cancer immunotherapy developed by Takara. The new immunotherapy uses RetroNectin®, Takara’s proprietary recombinant human fibronectin, to expand T-cells. More details...
Stock Symbol: (TSE: 4974)
|
Partner Events
September 16-18, 2008
San Francisco, CA
October 11-13, 2008
Dalian, China
November 9-11, 2008
Shanghai, China
>> More details...
|
.gif)
.gif)
.gif)
